Conference Scene: Pharmacogenomics at the Second Pharmscifair 2009: Adverse Drug Reactions and Clinical Implementation

Abstract

From 8th to 12th June 2009, the second PharmSciFair took place in Nice, France. Sessions were organized on different types of pharmaceutical research. Two pharmacogenomics sessions were organized by the European Federation for Pharmaceutical Sciences Network on Research in Pharmacogenetics/Pharmacogenomics. The topics of the sessions were adverse drug reactions and clinical implementation. Important conclusions of the presentations were that there has been much progress in the field of pharmacogenomics and that implementation in clinical practice is not as easy as it was once thought. Large prospective trials might be necessary to prove clinical relevance.

Acknowledgements

We would like to thank the organization of the PharmSciFair. The pharmacogenetic sessions were organized by the EUFEPS Research Network on Pharmacogenetics and Pharmacogenomics.

Financial & competing interests disclosure

Anke Hilse Maitland-van der Zee and Ingolf Cascorbi have a grant from the Innovation programme ASAT ‘Assuring Safety without Animal Testing‘ from the Dutch Government and unconditional grants from GlaxoSmithKline, Eli Lilly, Pfizer and Roche to conduct the pilot study on drug-induced liver injuries for the European Adverse Drug Reactions Biobank. Anke Hilse Maitland-van der Zee has an unconditional grant from GlaxoSmithKline to research the pharmacogenetics of asthma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Anke Hilse Maitland-van der Zee and Ingolf Cascorbi have a grant from the Innovation programme ASAT ‘Assuring Safety without Animal Testing’ from the Dutch Government and unconditional grants from GlaxoSmithKline, Eli Lilly, Pfizer and Roche to conduct the pilot study on drug-induced liver injuries for the European Adverse Drug Reactions Biobank. Anke Hilse Maitland-van der Zee has an unconditional grant from GlaxoSmithKline to research the pharmacogenetics of asthma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.